|Bid||0.00 x 1000|
|Ask||0.00 x 3200|
|Day's Range||6.80 - 7.07|
|52 Week Range||4.90 - 10.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.50|
CAMBRIDGE, Mass. , Aug. 30, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. ...
NEW YORK, Aug. 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Leap ...
CAMBRIDGE, Mass., Aug. 08, 2018-- Leap Therapeutics, Inc., a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial results for the second ...
Today, Leap Therapeutics (LPTX) entered into a collaborative agreement with Merck (MRK) and Pfizer (PFE) to evaluate TRX518, a GITR (glucocorticoid-induced tumor necrosis factor receptor) agonist, in combination with avelumab and chemotherapy for the treatment of advanced solid tumors. Leap Therapeutics plans to start enrolling patients in the Phase 1/2 clinical trial during the first quarter of 2019.
CAMBRIDGE, Mass., July 23, 2018-- Leap Therapeutics, Inc., a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into a collaboration agreement with ...
Leap Therapeutics (LPTX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Leap Therapeutics Inc (NASDAQ:LPTX), a USD$58.72M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...